---
layout: default
title: Apis Mellifera Apis Mellifera Venom Euphorbia Resi
parent: 僅模型預測 (L5)
nav_order: 372
evidence_level: L5
indication_count: 0
---

# Apis Mellifera Apis Mellifera Venom Euphorbia Resi
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Ingredient Botanical Combination (Homeopathic): Insufficient Data for Repurposing Evaluation

## One-Sentence Summary

This Evidence Pack describes a nine-ingredient botanical/homeopathic combination—including *Apis mellifera* venom, *Euphorbia resinifera* resin, histamine dihydrochloride, and six other botanicals—with no registered market authorization in Taiwan, no DrugBank mapping, and no TxGNN-generated repurposing predictions. Without a structured drug entity or predicted indication, a repurposing evaluation cannot be conducted at this stage. **No clinical trial or literature evidence is therefore available to support any specific new indication.**

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not established — no regulatory authorization found |
| Predicted New Indication | None — TxGNN did not generate predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | Below L5 (no model output, no studies) |
| Taiwan Market Status | ✗ Not marketed |
| Number of Licenses | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

TxGNN operates on single molecular entities mapped to the DrugBank knowledge graph. This candidate is a **nine-component mixture** of botanical extracts and homeopathic dilutions:

| Component | Category |
|-----------|---------|
| *Apis mellifera* / *Apis mellifera* venom | Animal-derived / bee venom peptides |
| *Euphorbia resinifera* resin | Botanical (contains resiniferatoxin, a TRPV1 agonist) |
| *Euphrasia stricta* | Botanical (eyebright, used in ocular complaints) |
| *Hedera helix* flowering twig | Botanical (ivy; saponins with expectorant activity) |
| Histamine dihydrochloride | Small molecule (homeopathic dilution) |
| Onion (*Allium cepa*) | Botanical (quercetin source) |
| *Pulsatilla vulgaris* | Botanical (pasque flower; used in homeopathy) |
| *Schoenocaulon officinale* seed | Botanical (sabadilla; alkaloids cevadine/veratridine) |

Because none of these components resolved to a DrugBank ID (`drugbank_id: null`), the TxGNN pipeline could not construct an entity embedding and therefore produced **zero predicted indications**. This is an expected pipeline behavior, not a data error.

Based on pharmacological knowledge of individual components, the combination pattern is consistent with **European homeopathic products** formulated for allergic rhinitis, insect-sting reactions, or upper respiratory complaints (e.g., products in the *Apis*/*Euphrasia*/*Histamine* category). However, this interpretation is **not derived from model output** and carries no evidentiary weight for repurposing decisions.

---

## Safety Considerations

No safety data is currently available for this combination as a mapped drug entity. Please refer to individual monographs and the original manufacturer's package insert.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The candidate could not be processed by TxGNN because it lacks a resolvable DrugBank identifier, resulting in zero predicted indications and zero supporting evidence. Without a structured drug entity, no repurposing hypothesis exists to evaluate.

**To proceed, the following is needed:**

- **Entity disambiguation**: Determine whether the intended active ingredient is a single lead compound (e.g., resiniferatoxin from *Euphorbia resinifera*, or melittin/phospholipase A₂ from bee venom) and obtain its DrugBank ID.
- **Regulatory clarification**: Confirm whether this combination is registered in any jurisdiction (EU, US, Japan) under a homeopathic or botanical drug pathway and retrieve the authorised indications.
- **MOA documentation**: Retrieve the mechanism of action for the primary active component from DrugBank or literature before re-submitting to the TxGNN pipeline.
- **Re-submission**: Once a single mappable entity is identified, re-run the TxGNN prediction pipeline for a standard repurposing evaluation.
- **Safety baseline**: Download the manufacturer's package insert (or the TFDA equivalent if one exists) to complete the S1 safety screening that is currently blocked (Data Gap DG001).
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

